LENZ Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | — | — | — |
| Operating income | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M |
| Operating expenses | — | $58.6M | $72.4M | $105.6M | $60.4M |
| Cost of revenue | $418,000 | $0 | — | — | — |
| Cash from operations | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M |
| Capital expenditure | $827,000 | $468,000 | $30,000 | $6.6M | $5.7M |
| Free cash flow | -$70.0M | -$59.9M | -$60.4M | -$94.6M | -$58.6M |
| Impairments | — | — | $54.1M | $0 | $0 |
| Total assets | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M |
| Total liabilities | $21.5M | $11.2M | $19.7M | $25.6M | $17.9M |
Shares outstanding 31.4M · Free float 41.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.